CEOP-IMVP-Dexa regimen

Primary end point of this trial was to reduce neutropenic infections during the treatment of aggressive NHL with CEOP/IMVP-Dexa… Expand

Abstract Background/Purpose Elderly lymphomas are usually defined as disease onset at age more than 60 years according to the… Expand

This study aimed to determine whether dose-dense therapy improves 3-year survival over the standard therapy for untreated… Expand

 

A 6-year-old male child was consulted in our ambulatory in Goundi missionary hospital in South Chad, in September 2001. He… Expand

A 6-year-old male child was consulted in our ambulatory in Goundi missionary hospital in South Chad, in September 2001. He… Expand

Primary end point of this trial was to reduce neutropenic infections during the treatment of aggressive NHL with CEOP/IMVP-Dexa… Expand

PURPOSE This trial evaluated the efficacy, toxicity, and practicability of a new intensive chemotherapy regimen in a multicenter… Expand

We report on a 28 year old Turkish woman, who was admitted to our hospital with the symptoms of malabsorption and protein-loosing… Expand

A combination of two non-cross-resistant regimens, CEOP and IMVP-Dexa given every 4 weeks, three to six times according to… Expand